Strengthen pre- and post-market regulation of AI medical devices
4 submissions. Each submission counts once for this shared ask. Counts do not measure importance or merit.
A shared ask groups requests for substantially the same action from three or more submissions when the group was created. Groups remain listed if withdrawals reduce their counts. AI models summarised recommendations, grouped them and checked the groups. The label summarises the requests; it is not a quote. A shared ask does not mean agreement on anything else.
Theme: AI in health care
Recommendations from submissions
Quotes are the submitter’s own words. Text taken from documents, including scanned pages read by text-recognition software, can differ from the PDF. Check the original. Extracts are chosen by an AI model. Submissions are listed in submission number order; recommendations follow their order on each submission’s page.
Australian Medical Association (AMA) Submission 95
Include AI scribes within the definition of software as a medical device.
Currently, AI scribes are not encompassed within the definition of ‘software as a medical device’, and this should be remedied urgently to protect both patients and doctors.
Royal Australian and New Zealand College of Radiologists Submission 117
Require AI labelling of training/testing populations, intended clinical context, limitations, contraindicated contexts and supervision; require software version numbers and regulator clarity on updates and relabelling after significant changes.
That AI systems are labelled with a description of their training and testing populations, the clinical context in which they are intended to be used, their limitations, the contexts in which they should not be used, and the level of supervision required. All software should carry a version number, and regulatory authorities should provide clarity on acceptable mechanisms for updating AI systems and the labelling requirements that follow significant changes.
Royal Australasian College of Surgeons Submission 118
Strengthen requirements for evaluation, monitoring and post-deployment surveillance of AI systems used in healthcare.
Strengthen requirements for evaluation, monitoring and post-deployment surveillance of AI systems used in healthcare.
Dr Samantha Pillay OAM Submission 153
Regulate AI tools by their actual use at scale, not marketing claims, so tools used for diagnosis or treatment come under the TGA whatever their fine print says.
AI tools should be regulated by their actual use at scale, not their marketing claims, so that tools used for diagnosis or treatment come under the TGA whatever their fine print says.